selegiline in comparison with methylphenidate in treatment of adults with attention deficit yperactivity disorder: a double-blind, randomized trial

o b j ective: attention-deficit/hyperactivity disorder (adhd) is one of the most common mental disorders in childhood and it continues to adulthood without proper treatment. stimulants have been used in treatment of adhd for many years and the efficacy of methylphenidate (mph) in the treatment of adults with adhd has been proven to be acceptable according to meta-analysis studies. however, there are some concerns about stimulants. finding other effective medications for the treatment of adult adhd seems necessary. we tried a monoamine oxidase inhibitor, selegiline, as there are some theoretical and experimental evidences for the efficacy of this medication. m ethod: forty patients were randomized to receive selegiline or methylphenidate in an equal ratio for an 8-week double-blind clinical trial. each patient filled the caars self report screening form before starting to take the medication and in weeks 2-4-6 and 8. patients were also assessed by a psychiatrist at the baseline and on each 14 days up to the 8 weeks period. results: the mean score of the two groups- receiving selegiline or methylphenidate- decreased over the 8 weeks. there was not a significant difference between the two groups. the most prevalent side-effect of methylphenidate was decrease of appetite and for selegiline change in sleep pattern. conclusion: selegiline is as effective as methylphenidate in the treatment of adults  with  attention-deficit/hyperactivity disorder.  selegiline  can  be  an alternative medication for the treatment of adult adhd if its clinical efficacy is proven by other larger studies.